Navigation Links
Perrigo Provides Update on Acquisition of Paddock Labs
Date:6/29/2011

ALLEGAN, Mich., June 29, 2011 /PRNewswire/ -- Perrigo Company (Nasdaq: PRGO;TASE) today announced that it continues to work to finalize  the regulatory approvals necessary to complete the acquisition of Paddock Laboratories, Inc. ("Paddock"), a privately-held, Minneapolis-based pharmaceutical manufacturer of generic Rx pharmaceuticals and OTC specialty products.

Perrigo Chairman and CEO Joseph C. Papa stated, "We are looking forward to concluding the transaction as soon as possible. As we previously stated, we expect the transaction to be $0.25 accretive to adjusted earnings per share in fiscal year 2012. We have recently received a few additional questions from the Federal Trade Commission Staff and the Parties are working collaboratively with the Staff to answer these questions so that the FTC may conclude its review.  Since the close will now happen in our fiscal year 2012, we expect to incur $0.20 of deal-related intangible amortization and $0.15 of other acquisition-related costs, making it approximately $0.10 dilutive to GAAP earnings per share. Perrigo's stated goal of Return on Invested Capital accretion is expected to be achieved in fiscal 2013. This acquisition is an important step forward in executing Perrigo's strategy to expand our specialty portfolio of generic Rx products. It adds incremental scale, as well as excellent development and manufacturing capabilities across a spectrum of niche dosage forms. It solidifies Perrigo's leading position in the extended topical space and strengthens our ability to offer new products into the market. Paddock has a proven record for quality manufacturing with great customer service."

As previously highlighted, Perrigo expects to receive a significant tax benefit generated from the acquisition of Paddock's assets. The net present value of the tax benefit is estimated to be $95 million. Inclusive of the tax benefit, the total consideration for the acquisition is approximately $445 million
'/>"/>

SOURCE Perrigo Company
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Perrigo Announces Launch of the Generic Version of Nasacort® AQ
2. Perrigo Company to Present at the Goldman Sachs 32nd Annual Global Health Care Conference
3. Perrigos Partner Synthon Receives FDA Tentative Approval for Levocetirizine Solution - Generic Equivalent to Xyzal® Oral Solution
4. Perrigo Announces FDA Final Approval for Ranitidine 150 - Generic Equivalent to Zantac 150®
5. Perrigo Announces Settlement of Cutivate Lotion Litigation
6. Perrigo to Introduce New Dosing System and Labeling for Certain Pediatric Pain Relievers
7. Perrigo Reports Record Quarterly Revenue and Earnings and Raises Full Year Adjusted EPS Guidance
8. Perrigo Announces FDA Final Approval for Minoxidil Foam - Generic Equivalent to Mens Rogaine® Foam
9. Perrigo Company Announces Quarterly Dividend
10. Perrigos PBM Infant Formula Unit Wins Appellate Judgment Versus Mead Johnson
11. Perrigo Partner Teva Receives Final OTC Approval for Sales and Distribution of Fexofenadine HCl 60 mg and 180 mg Tablets
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/19/2014)... 19, 2014 Today, iHealth Lab Inc. announced it ... Ltd. for its first institutional round of funding. The ... global reach, accelerate growth and innovation, and invest in ... investment, Xiaomi Ventures will join iHealth,s board of directors, ... and ecommerce. "We are very pleased to ...
(Date:9/19/2014)... 19, 2014  The board of directors of AbbVie ... cash dividend of $0.42 per share.  ... stockholders of record at the close of business on ... a global, research-based biopharmaceutical company formed in 2013 following ... its expertise, dedicated people and unique approach to innovation ...
(Date:9/19/2014)... 2014 Research and Markets has announced ... Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023" ... of this report, the human microbiome market is segmented by ... market is expected to be valued as $294 million in ... 22.3% within the forecast period of 2019-2023. The market is ...
Breaking Medicine Technology:iHealth Raises $25 Million to Fuel Growth and Global Market Share 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 2Global Human Microbiome (Diabetes, Obesity, Autoimmune, Cancer, Diarrhea, Mental Disorder) Market - Forecast to 2023 3
... Va., Sept. 20, 2011 Rock Creek Pharmaceuticals, a ... ), announced that on September 19, 2011 a utility ... Office ("PTO"). This utility patent application is based on ... various products containing anatabine and the administration of anatabine ...
... Sept. 20, 2011 /PRNewswire-Asia/ -- Chindex International, Inc. (NASDAQ: ... providing health care services in China through the operations ... care hospitals and affiliated ambulatory clinics, today announced that ... to be held October 13-14, 2011 at Nomura,s Singapore ...
Cached Medicine Technology:Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing 2Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing 3Rock Creek Pharmaceuticals Discloses Further Anatabine Patent Filing 4
(Date:9/19/2014)... In partnership with Raw Beauty NYC, OC healthcare ... project’s social media efforts. StudioPMG is honored to be a ... of beauty as it applies to disabled women. , ... Baer and Vanessa Silberman, who wanted to create a photo ... Dixon, Wendy Crawford, Susan Solman and Sabrina Cohen later joined ...
(Date:9/19/2014)... September 19, 2014 -- Recent two-generation approaches to ... are receiving increasing attention from researchers, advocates, and ... to enable them to move to jobs that ... early care and education for children, these programs ... However, according to a new report from ...
(Date:9/19/2014)... 2014 As summer vacations end and everyone ... NY now reminds area patients about the reality and impact ... population affected by gum disease, there is simply not an ... 20 years Dr. Krishnan has treated patients with varying degrees ... patients that come in due to common symptoms such as ...
(Date:9/19/2014)... Recently, Top10BestSEOHosting.com has compared many professional ... Web Hosting and Bluehost are the best VPS ... to most people, VPS (Virtual Private Server) is ... into many servers, each of which has the ... dedicated computer,” the manager of Top10BestSEOHosting.com says. ...
(Date:9/19/2014)... and large protein complexes are notoriously difficult to study ... very difficult, if not impossible, to crystallize, but also ... The result is that when a structure can be ... reveals a mosaic-like spread of protein domains that sometimes ... Brunger. (2014), Acta Cryst . D70, 2241-2255; ...
Breaking Medicine News(10 mins):Health News:OC Healthcare Agency StudioPMG Partners with The Raw Beauty Project ™ NYC 2014 2Health News:A two generation lens: Current state policies fail to support families with young children 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 2Health News:New York Periodontist Dr. Prabha Krishnan Now Raises Awareness about the Dangers of Untreated Decay, Gingivitis and Gum Disease During Self-Awareness Month 3Health News:Top10BestSEOHosting.com: JustHost is One of the Best VPS Suppliers in 2014 2Health News:A refined approach to proteins at low resolution 2Health News:A refined approach to proteins at low resolution 3
... LA JOLLA, Calif., Jan. 29 There,s a rumble ... their feet and planting,their behinds on yoga mats and ... World Health Research shows that,74% of Americans have expressed ... A surge in popularity of Pilates, Yoga, Qigong, Meditation, ...
... recurrence and painful side effects, small trial finds , , ... to treating deep vein thrombosis, injecting the clot-busting drug ... the risk of complications and recurrence, a small U.S. ... of blood thinners appears to completely destroy the clots, ...
... Opportunities for the Company, -- Potentially Denotes a Positive Sign ... ... Process, NEW YORK and HAIKOU, China, ... Board: CPHI),which develops, manufactures, and markets generic and brand,bio-pharmaceutical products in ...
... Ind., Jan. 29 , ... Quarter Highlights, -- Net Sales of $1.07 billion represents an increase of 15% ... 15% reported (10% constant currency), -- Diluted EPS were ... period, and $1.18 adjusted, an increase of 16% over the prior year ...
... MS -- Cold and flu season is upon ... year, according to,the Centers for Disease Control. A cold ... in children and the elderly. Early detection,is key, especially ... days,of the infection,s onset., (Photo: http://www.newscom.com/cgi-bin/prnh/20080129/NYTUFNS1 ...
... for blood clots in the legs appears to be safe ... February issue of Radiology. The study found that injecting or ... deep vein thrombosis (DVT) and reduces the risk of subsequent ... clear blood clots rapidly and safely, restoring blood flow in ...
Cached Medicine News:Health News:Are People Asking Their Doctors?: Halo Rejuvenator a Holistic Remedy for Headache, Neck and Shoulder Pain 2Health News:Are People Asking Their Doctors?: Halo Rejuvenator a Holistic Remedy for Headache, Neck and Shoulder Pain 3Health News:Clot-Busting Drug Offers New Approach to DVT 2Health News:Clot-Busting Drug Offers New Approach to DVT 3Health News:China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection 2Health News:China Pharma Holdings, Inc. Receives Chinese SFDA Approval for Generic Bumetanide Injection 3Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 2Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 3Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 4Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 5Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 6Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 7Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 8Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 9Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 10Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 11Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 12Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 13Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 14Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 15Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 16Health News:Zimmer Reports Fourth Quarter and 2007 Financial Results 17Health News:Flu and Fever Detection Facts for Dr. Mom 2Health News:Flu and Fever Detection Facts for Dr. Mom 3Health News:New therapy effectively treats deep vein thrombosis 2
Provides the security of braided polyester suture and ease of an automated knot for vascular closure of 5-8Fr....
The ACE Alera clinical chemistry system serves a wide variety of chemistry diagnostic needs with the power of a large floor model analyzer in an easily integrated and economizing compact footprint of...
... reference laboratory and a worldwide leader in ... an extensive test menu of highly complex ... anatomic pathology. Owned by the University of ... half of the nation's university teaching hospitals ...
... national reference laboratory and a worldwide leader ... offers an extensive test menu of highly ... and anatomic pathology. Owned by the University ... than half of the nation's university teaching ...
Medicine Products: